BALTIMORE, July 19 /PRNewswire/ -- Lupin Ltd. announced today that the United States District Court for the Eastern District of Virginia has issued an opinion following the completion of a trial on sanofi-aventis’ U.S. Patent No. 5,061,722 relating to Altace(R) and found the patent to be valid.
Commenting on the judgment, Dr. Kamal Sharma, Managing Director of Lupin Ltd., said, “We are disappointed that the judge found the patent to be valid, albeit reluctantly and we have filed an appeal of this decision to the Federal Circuit.”
The court decision arises from a suit filed by King Pharmaceuticals and sanofi-aventis against the Company alleging patent infringement on the 5,061,722 patent listed in the FDA’s Orange Book. The trial was completed in June 2006.
About Lupin
Headquartered in Mumbai, Lupin Ltd. is a leading pharmaceutical company with a strong research focus. It has a program for developing New Chemical Entities. The Company has a state-of-the-art R&D center in Pune. The Company is a leading global player in Anti-TB, Cephalosporins (anti-infectives) and Cardiovascular drugs (prils and statins) and has a notable presence in the areas of diabetology, NSAIDs and Asthma.
For the financial year ended March 2006, the Company’s Revenues and Profit after Tax were Rs.16,610 million (US$ 375 million) and Rs.1,827 million (US$ 41 million), respectively. Please visit http://www.lupinworld.com for more information about Lupin Ltd.
Lupin Pharmaceuticals, Inc. is the U.S. wholly owned subsidiary of Lupin Limited, which is among the top six Pharmaceutical companies in India. Through its sales and marketing headquarters in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. is dedicated to delivering high-quality, affordable generic medicines trusted by healthcare professionals and patients across geographies. For more information, visit http://www.lupinpharmaceuticals.com.
Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act of 1995:
This release contains forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Many of these risks, uncertainties and other factors include failure of clinical trials, delays in development, registration and product approvals, changes in the competitive environment, increased government control over pricing, fluctuations in the capital and foreign exchange markets and the ability to maintain patent and other intellectual property protection. The information presented in this release represents management’s expectations and intentions as of this date. Lupin expressly disavows any obligation to update the information presented in this release.
Contact: Leslie Leader
Office Manager 410-576-2000
Lupin Pharmaceuticals, Inc.
CONTACT: Leslie Leader, Office Manager, Lupin Pharmaceuticals, Inc.,+1-410-576-2000
